Patients | Reference value | ||
---|---|---|---|
Age (yr) b | 54.2 ± 10.6 | ||
Male/Female (ratio) | 14/16 (0.47) | ||
BMI (kg/m2) b | 23.7 ± 2.7 | 18.5 - 25 | |
ALT (IU/L) a | 47.5 (17–167) | 8 - 42 | |
γGTP (IU/L) a | 41 (13–152) | 10 - 47 | |
ChE (IU/L) b | 312.9 ± 88.2 | 185 - 431 | |
Fasting plasma glucose (mg/dL) b | 95.5 ± 9.7 | 70 - 109 | |
Insulin (μIU/mL) a | 8.7 (4.5 - 20.4) | 1.84 - 12.2 | |
HOMA-IR a | 2.0 (1.2 - 5.1) | ||
HOMA-IR > 2.5 (%) | 9 (30) | ||
Triglyceride (mg/dL) b | 91.4 ± 31.1 | 30 - 149 | |
Total cholesterol (mg/dL) b | 175.2 ± 25.4 | 129 - 219 | |
Acylcarnitine (μmol/L) a | 9.25 (5.7 - 21.1) | 6 - 23 | |
HCV RNA (LogIU/mL) b | 6.1 ± 0.9 | ||
HCV core antigen (fmol/L) a | 6505 (<20–23200) | ||
HCV Genotype | 1b / 2a / 2b | 20 / 6 / 4 | |
Inflammation | A0 / A1 / A2 / A3 | 0 / 15 / 10 / 0 | |
Fibrosis | F0 / F1 / F2 / F3 / F4 | 0 / 15 / 7 / 3 / 0 | |
Steatosis | G0 / G1 / G2 / G3 | 6 /18 / 1 / 0 |